Successful Treatment of Facial Pseudolymphoma With Intravenous Rituximab: A Case Report

Intravenous rituximab demonstrated significant efficacy in treating a case of refractory cutaneous pseudolymphoma that failed multiple conventional therapies, including corticosteroids, hydroxychloroquine, methotrexate, and biologics. The patient, a 42-year-old man, initially developed erythematous, nodular lesions on the face following dental implant surgery, which later spread and persisted despite various immunosuppressive and anti-inflammatory treatments. Histopathological and immunohistochemical analysis confirmed B-cell pseudolymphoma. Intravenous rituximab (500 mg weekly for 4 weeks, followed by maintenance doses) led to substantial lesion regression, with no recurrence observed after 1 year of follow-up. This case underscores the therapeutic potential of rituximab for treatment-resistant pseudolymphoma and highlights the need for further research into optimal treatment protocols for this rare condition.